^○Ken INADA¹, Jun ISHIGOOKA², Sakiko YAMADA³, Hisashi AKIYOSHI³, Shuichi IWASHITA³, Tomohiro USAMI³ (1. Tokyo Women's Medical University, Tokyo, Japan, 2. Institute of CNS Pharmacology, Tokyo, Japan, 3. Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan)

^○Masaki KATO¹, Yuko ASAMI², Dalia WAJSBROT⁴, Matthieu BOUCHER³, Rita PRIETO⁵, Xuemei WANG⁶, Elizabeth PAPPADOPULOS⁴ (1. Department of Neuropsychiatry, Kansai Medical University, 2. Pfizer Japan Inc., Tokyo, Japan, 3. Pfizer Canada Inc., Kirkland, QC, Canada and McGill University, Montréal, QC, Canada, 4. Pfizer Inc., New York, NY, USA, 5. Pfizer GEP SLU, Madrid, Spain , 6. Syneos Health Inc., Raleigh)

^○AYANO KASHIHARA¹, Yosuke KOSHIKAWA¹, Yoshiteru TAKEKITA¹, Sakai SHIHO¹, Naotaka SUNADA¹, Hiroki BANDOU², Keiichiro NISHIDA¹, Haruhiko OGATA^{1, 2}, Toshihiko KINOSHITA¹, Masaki KATO¹ (1. Department of Neuropsychiatry, Kansai Medical University, 2. Seishokai Sephiroth Hospital)

^○Saki HATTORI¹, Akira SUDA¹, Ikuko KISHIDA^{1, 2}, Masatoshi MIYAUCHI¹, Yohko SHIRAISHI¹, Mami FUJIBAYASHI³, Natsuki TSUJITA⁴, Norio ISHII², Chie ISHII², Toshio MORITANI⁵ (1. Department of Psychiatry, Yokohama City University School of Medicine, 2. Fujisawa Hospital, 3. Division of Physical and Health Education, Setsunan University, 4. Graduate School of Human and Environmental Studies, Kyoto University, 5. Faculty of General Education, Kyoto Sangyo University)